CTS-IPITA-IXA 2007 Joint Conference

本拨款申请是为了请求美国国立卫生研究院为2007年该小组联席会议提供支持。 移植学会(CTS)、国际胰腺和胰岛移植协会(IPITA)和国际 异种移植协会(IXA)。移植学会三个分会的首次联席会议 (TTS)将于2007年9月15日至20日在明尼苏达州明尼阿波利斯举行(www.cts-ipita-ixa-007.org)。 2007年联合会议将是TTS和#年移植研究界的一件大事 2007年。这将是两年内胰腺、胰岛、细胞和异种移植领域的首要事件。 跨度。鉴于越来越多的移植活动，这次会议将是及时和重要的，主要 在这四个领域取得了前所未有的进展和机遇： ？胰腺：每年近2,000例移植，包括1,250例同时进行的胰腺和肾脏移植。 ？胰岛：北美的42个胰岛移植计划；完成后预计活动将大幅增加 2期III许可试验(由NIH临床胰岛移植联合会资助)在患有和 没有以前的肾移植手术。在欧洲、澳大利亚和亚洲有20多个活跃的项目。 ？细胞移植：细胞治疗的新机会(例如，肝脏、胰岛、神经组织和 心脏置换和搭桥；再生和生长因子；细胞免疫疗法)。 ？异种移植：猪到非人灵长类动物心脏、肾脏和胰岛的巨大增加 过去两年的异种移植存活率(例如，《自然医学》上的四篇论文)。 在Megan Sykes，医学博士，Science，Megan Sykes的领导下，制定了一个出色的科学计划 项目主席。100多位国际知名演讲者将介绍进展和新兴 细胞和器官的同种移植和异种移植治疗多种肿瘤的机会 精神错乱。该计划将包括全体会议、座谈会、研讨会、口头摘要会议和 海报会议。这项活动的规划和实施是按照基本领域和 继续医学教育评审委员会(ACCME)的政策，通过赞助 TTS。 2007年联席会议预计将有1000多名代表出席，因此将负担得起 出席会议的临床研究人员和基础科学家提供了介绍和讨论最新进展的绝佳机会 研究成果。这也将为在这些相关领域工作的科学家提供第一次机会 并从它们互补的专业知识和经验中进行互动并从中受益。 R13拨款将是我们目标的一个关键因素，即提供一个最高科学水平的国际论坛 将导致更多地利用移植治疗糖尿病、心力衰竭、肝脏的优点 疾病、肌肉营养不良、神经退行性疾病和其他适应症。

This grant application is submitted to request support from NIH for the 2007 Joint Conference of the Cell Transplant Society (CTS), International Pancreas and Islet Transplant Association (IPITA), and International Xenotransplantation Association (IXA). This first joint meeting of 3 sections of The Transplantation Society (TTS) will take place in Minneapolis, MN from September 15-20, 2007 (www.cts-ipita-ixa-007.org). The 2007 Joint Conference will be the major event of the TTS and of the transplant research community in 2007. It will be the premier event in the areas of pancreas, islet, cell, and xenotransplantation in a 2-year time span. The meeting will be timely and important in light of the increasing transplant activity, major developments, and unprecedented progress and opportunities in these four areas: ? Pancreas: Close to 2,000 transplants annually, including 1,250 simultaneous pancreas-kidney transplants. ? Islets: 42 islet transplant programs in North America; major increase in activity expected after completion of 2 Phase III licensure trials (funded by the NIH Clinical Islet Transplant Consortium) in patients with and w/o previous kidney transplants. More than 20 active programs in Europe, Australia, and Asia. ? Cell Transplantation: Emerging opportunities for cellular therapeutics (e.g., liver, islet, neural tissue and heart replacement and bridging; regeneration and growth factors, cellular immunotherapeutics). ? Xenotransplantation: Immense increase in pig-to-nonhuman primate heart, kidney, and islet xenotransplant survival in past 2 years (e.g., four publications in Nature Medicine). An excellent scientific program has been developed under the leadership of Megan Sykes, MD, Scientific Program Chair. More than 100 internationally renowned speakers will present progress and emerging opportunities in allotransplantation and xenotransplantation of cells and organs for the treatment of a variety of disorders. The program will include Plenary Sessions, Symposia, Workshops, Oral Abstract Sessions, and Poster Sessions. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of TTS. The 2007 Joint Conference is expected to be attended by more than 1,000 delegates and will therefore afford attending clinical investigators and basic scientists an excellent opportunity to present and discuss latest research findings. It will present also the first opportunity for scientists working in these related areas to meet and interact and benefit from their complementary expertise and experience. The R13 grant will be a key element in our objective of providing an international forum of the highest scientific merit that will result in increased utilization of transplantation for the treatment of diabetes, heart failure, liver diseases, muscular dystrophies, neurodegenerative disorders, and other indications.